Spampinato, M.; Zuppelli, T.; Dulcamare, I.; Longhitano, L.; Sambataro, D.; Santisi, A.; Alanazi, A.M.; Barbagallo, I.A.; Vicario, N.; Parenti, R.;
et al. Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia. Pharmaceuticals 2024, 17, 894.
https://doi.org/10.3390/ph17070894
AMA Style
Spampinato M, Zuppelli T, Dulcamare I, Longhitano L, Sambataro D, Santisi A, Alanazi AM, Barbagallo IA, Vicario N, Parenti R,
et al. Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia. Pharmaceuticals. 2024; 17(7):894.
https://doi.org/10.3390/ph17070894
Chicago/Turabian Style
Spampinato, Mariarita, Tatiana Zuppelli, Ilaria Dulcamare, Lucia Longhitano, Domenico Sambataro, Annalisa Santisi, Amer M. Alanazi, Ignazio A. Barbagallo, Nunzio Vicario, Rosalba Parenti,
and et al. 2024. "Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia" Pharmaceuticals 17, no. 7: 894.
https://doi.org/10.3390/ph17070894
APA Style
Spampinato, M., Zuppelli, T., Dulcamare, I., Longhitano, L., Sambataro, D., Santisi, A., Alanazi, A. M., Barbagallo, I. A., Vicario, N., Parenti, R., Romano, A., Musumeci, G., Li Volti, G., Palumbo, G. A., Di Raimondo, F., Nicolosi, A., Giallongo, S., & Del Fabro, V.
(2024). Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia. Pharmaceuticals, 17(7), 894.
https://doi.org/10.3390/ph17070894
